Abstract
3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DAex) and serotonin (5-HTex) levels in the striatum and prefrontal cortex (PFC) using in vivo microdialysis techniques in mice lacking DA transporters (DAT) and/or 5-HT transporters (SERT). Subcutaneous injection of MDMA (3, 10 mg/kg) significantly increased striatal DAex in wildtype mice, SERT knockout mice, and DAT knockout mice, but not in DAT/SERT double-knockout mice. The MDMAinduced increase in striatal DAex in SERT knockout mice was significantly less than in wildtype mice. In the PFC, MDMA dose-dependently increased DAex levels in wildtype, DAT knockout, SERT knockout and DAT/SERT doubleknockout mice to a similar extent. In contrast, MDMA markedly increased 5-HTex in wildtype and DAT knockout mice and slightly increased 5-HTex in SERT-KO and DAT/SERT double-knockout mice. The results confirm that MDMA acts at both DAT and SERT and increases DAex and 5-HTex.
Keywords: MDMA, serotonin transporter, dopamine transporter, knockout, microdialysis, Hallucinogenic agents, Sodium pentobarbital, Fluoxetine, Knock Out, Norpherine (NE), Psychostimulants, Prefrontal Cortex (PFC)
Current Neuropharmacology
Title: Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
Volume: 9 Issue: 1
Author(s): Y. Hagino, Y. Takamatsu, H. Yamamoto, T. Iwamura, D. L. Murphy, G. R. Uhl, I. Sora and K. Ikeda
Affiliation:
Keywords: MDMA, serotonin transporter, dopamine transporter, knockout, microdialysis, Hallucinogenic agents, Sodium pentobarbital, Fluoxetine, Knock Out, Norpherine (NE), Psychostimulants, Prefrontal Cortex (PFC)
Abstract: 3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DAex) and serotonin (5-HTex) levels in the striatum and prefrontal cortex (PFC) using in vivo microdialysis techniques in mice lacking DA transporters (DAT) and/or 5-HT transporters (SERT). Subcutaneous injection of MDMA (3, 10 mg/kg) significantly increased striatal DAex in wildtype mice, SERT knockout mice, and DAT knockout mice, but not in DAT/SERT double-knockout mice. The MDMAinduced increase in striatal DAex in SERT knockout mice was significantly less than in wildtype mice. In the PFC, MDMA dose-dependently increased DAex levels in wildtype, DAT knockout, SERT knockout and DAT/SERT doubleknockout mice to a similar extent. In contrast, MDMA markedly increased 5-HTex in wildtype and DAT knockout mice and slightly increased 5-HTex in SERT-KO and DAT/SERT double-knockout mice. The results confirm that MDMA acts at both DAT and SERT and increases DAex and 5-HTex.
Export Options
About this article
Cite this article as:
Hagino Y., Takamatsu Y., Yamamoto H., Iwamura T., L. Murphy D., R. Uhl G., Sora I. and Ikeda K., Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017254
DOI https://dx.doi.org/10.2174/157015911795017254 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species
Current Molecular Medicine Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Schizophrenia and Nicotine Dependence: What Psychopharmacological Treatment Options are Available for the Duo Perturbationes?
Current Drug Targets Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Nuances in Alzheimer’s Genetic Risk Reveal Differential Predictions of Non-demented Memory Aging Trajectories: Selective Patterns by APOE Genotype and Sex
Current Alzheimer Research Pharmacological Approaches of Neurofibrillary Degeneration
Current Alzheimer Research Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine
Anti-Cancer Agents in Medicinal Chemistry sAPP Enhances the Transdifferentiation of Adult Bone Marrow Progenitor Cells to Neuronal Phenotypes
Current Alzheimer Research Designer Drugs on the Internet: A Phenomenon Out-of-Control? The Emergence of Hallucinogenic Drug Bromo-Dragonfly
Current Clinical Pharmacology Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
CNS & Neurological Disorders - Drug Targets Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research Non-Analgesic Effects of Opioids: Management of Opioid-Induced Constipation by Peripheral Opioid Receptor Antagonists: Prevention or Withdrawal?
Current Pharmaceutical Design The Era of Cerebellar Therapy
Current Neuropharmacology Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Measurement of myo-Inositol in Biological Systems by Mass Spectrometric and In Vivo 1H Magnetic Resonance Spectroscopic Techniques
Current Organic Chemistry Chemistry and Biology of Gluten Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)